The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients

Nephron

Volumn 92, Issue 1, 2002, Pages 120-126

  Haviv, Y S ^a,b   Shpichinetsky, V ^a   Goldschmidt, N ^a   Abou Atta, I ^a   Ben Yehuda, A ^a   Friedman, G ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cardiovascular disease; Hemodialysis; Homocysteine; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; NUCLEOTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; HEMODIALYSIS; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; WILD TYPE;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; PREVALENCE; RENAL DIALYSIS; RISK FACTORS;

EID: 0036377016     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064485     Document Type: Article

References (33)

1. Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke
2. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: A case-control study
3. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
4. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
5. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
6. 12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients
7. The effect of renal transplantation on hyperhomocysteinaemia in dialysis patients, and the estimation of renal homocysteine extraction in patients with normal renal function
8. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
9. The common 'thermolabile' variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia
10. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: Association with plasma total homocysteine and folate concentrations
11. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase (MTHFR) gene and the risk for diabetic nephropathy in type II diabetic patients
12. A second common mutation in the methylenetetrahydrofolate reductase: An additional risk factor for neural-tube defects?
13. Value of 24-hour ECG Holter monitoring in the evaluation of painless episodes of ST segment depression in patients with ischemic heart disease
14. Heart rate, magnitude and duration of ST-segment depression in symptomatic and asymptomatic episodes of myocardial ischemia in patients with coronary artery disease recorded by Holter
15. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer
16. A simple salting out procedure for extracting DNA from human nucleated cells
17. Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease
18. Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins
19. Pathophysiology of cardiovascular disease in hemodialysis patients
20. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
21. Transient ST segment depression during Holter monitoring: How to avoid false-positive findings
22. Cardiovascular risk factors in chronic renal failure and hemodialysis populations
23. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis
24. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
25. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
26. Do dialysis patients need extra folate supplementation?
27. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study
28. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients
29. Effect of methylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients
30. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
31. Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism
32. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
33. 12, serum and erythrocyte folate in peritoneal dialysis patients